Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1947 2
1949 2
1950 5
1951 2
1957 2
1958 1
1959 1
1960 2
1962 3
1963 4
1964 4
1965 2
1967 1
1968 8
1969 15
1970 21
1971 20
1972 23
1973 17
1974 16
1975 17
1976 11
1977 19
1978 12
1979 18
1980 20
1981 32
1982 43
1983 29
1984 28
1985 25
1986 43
1987 64
1988 49
1989 76
1990 101
1991 97
1992 137
1993 137
1994 126
1995 114
1996 150
1997 165
1998 187
1999 229
2000 283
2001 317
2002 315
2003 320
2004 350
2005 384
2006 395
2007 415
2008 394
2009 344
2010 343
2011 386
2012 423
2013 440
2014 401
2015 431
2016 394
2017 361
2018 337
2019 157
2020 14
Text availability
Article attribute
Article type
Publication date

Search Results

8,541 results
Results by year
Filters applied: . Clear all
Page 1
Combined adult neurogenesis and BDNF mimic exercise effects on cognition in an Alzheimer's mouse model.
Choi SH, Bylykbashi E, Chatila ZK, Lee SW, Pulli B, Clemenson GD, Kim E, Rompala A, Oram MK, Asselin C, Aronson J, Zhang C, Miller SJ, Lesinski A, Chen JW, Kim DY, van Praag H, Spiegelman BM, Gage FH, Tanzi RE. Choi SH, et al. Science. 2018 Sep 7;361(6406):eaan8821. doi: 10.1126/science.aan8821. Science. 2018. PMID: 30190379 Free PMC article.
Selective RET kinase inhibition for patients with RET-altered cancers.
Subbiah V, Velcheti V, Tuch BB, Ebata K, Busaidy NL, Cabanillas ME, Wirth LJ, Stock S, Smith S, Lauriault V, Corsi-Travali S, Henry D, Burkard M, Hamor R, Bouhana K, Winski S, Wallace RD, Hartley D, Rhodes S, Reddy M, Brandhuber BJ, Andrews S, Rothenberg SM, Drilon A. Subbiah V, et al. Ann Oncol. 2018 Aug 1;29(8):1869-1876. doi: 10.1093/annonc/mdy137. Ann Oncol. 2018. PMID: 29912274 Free PMC article. Clinical Trial.
Brigatinib in Patients With Alectinib-Refractory ALK-Positive NSCLC.
Lin JJ, Zhu VW, Schoenfeld AJ, Yeap BY, Saxena A, Ferris LA, Dagogo-Jack I, Farago AF, Taber A, Traynor A, Menon S, Gainor JF, Lennerz JK, Plodkowski AJ, Digumarthy SR, Ou SI, Shaw AT, Riely GJ. Lin JJ, et al. J Thorac Oncol. 2018 Oct;13(10):1530-1538. doi: 10.1016/j.jtho.2018.06.005. Epub 2018 Jun 20. J Thorac Oncol. 2018. PMID: 29935304 Free PMC article. Clinical Trial.
Modified carbazoles destabilize microtubules and kill glioblastoma multiform cells.
Diaz P, Horne E, Xu C, Hamel E, Wagenbach M, Petrov RR, Uhlenbruck B, Haas B, Hothi P, Wordeman L, Gussio R, Stella N. Diaz P, et al. Eur J Med Chem. 2018 Nov 5;159:74-89. doi: 10.1016/j.ejmech.2018.09.026. Epub 2018 Sep 11. Eur J Med Chem. 2018. PMID: 30268825 Free PMC article.
Primary prophylaxis of variceal bleeding.
Robertson M, Hayes P. Robertson M, et al. Hepatol Int. 2018 Jan;12(1):1-5. doi: 10.1007/s12072-018-9846-1. Epub 2018 Feb 2. Hepatol Int. 2018. PMID: 29396732 No abstract available.
Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study.
Novello S, Mazières J, Oh IJ, de Castro J, Migliorino MR, Helland Å, Dziadziuszko R, Griesinger F, Kotb A, Zeaiter A, Cardona A, Balas B, Johannsdottir HK, Das-Gupta A, Wolf J. Novello S, et al. Ann Oncol. 2018 Jun 1;29(6):1409-1416. doi: 10.1093/annonc/mdy121. Ann Oncol. 2018. PMID: 29668860 Free PMC article. Clinical Trial.
Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study.
Gadgeel S, Peters S, Mok T, Shaw AT, Kim DW, Ou SI, Pérol M, Wrona A, Novello S, Rosell R, Zeaiter A, Liu T, Nüesch E, Balas B, Camidge DR. Gadgeel S, et al. Ann Oncol. 2018 Nov 1;29(11):2214-2222. doi: 10.1093/annonc/mdy405. Ann Oncol. 2018. PMID: 30215676 Free PMC article. Clinical Trial.
Alectinib: A Review in Advanced, ALK-Positive NSCLC.
Paik J, Dhillon S. Paik J, et al. Drugs. 2018 Aug;78(12):1247-1257. doi: 10.1007/s40265-018-0952-0. Drugs. 2018. PMID: 30030733 Review.
8,541 results
Jump to page
Feedback